Synonyms: Example 130 [US20140194408] | GDC-0853 | GDC0853 | RG-7845 | RG7845
Compound class:
Synthetic organic
|
|
No information available. |
Summary of Clinical Use ![]() |
GDC-0853 was reported to be well tolerated with no dose-limiting adverse events in phase 1 studies in healthy volunteers [3]. It was advanced to clinical evaluations is patients with B-cell malignancies, and to determine efficacy against difficult-to-treat autoimmune or inflammatory conditions. GDC-0853 has demonstrated efficacy to reduce brain lesions in multiple sclerosis in phase 2 clinical study (NCT05119569) [5] (unpublished findings). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02833350 | Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) | Phase 2 Interventional | Genentech, Inc. | ||
NCT02908100 | A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus | Phase 2 Interventional | Genentech, Inc. | 4 | |
NCT04586023 | Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Phase 3 Interventional | Hoffmann-La Roche | ||
NCT05119569 | A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) | Phase 2 Interventional | Hoffmann-La Roche |